Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | MAOB | P27338 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4960027 | 1.00 | HTR2A (0.33) | HTR2AHTR2CCYP19A1NPC1L3MBTL1 | |
| SCHEMBL4962960 | 0.88 | NPC1 (0.33) | HTR2AHTR2CCYP19A1NPC1L3MBTL1 | |
| SCHEMBL4962953 | 0.88 | NPC1 (0.33) | HTR2AHTR2CCYP19A1NPC1L3MBTL1 | |
| SCHEMBL4963002 | 0.86 | NPC1 (0.37) | HTR2AHTR2CCYP19A1NPC1L3MBTL1 | |
| SCHEMBL4962999 | 0.86 | NPC1 (0.37) | HTR2AHTR2CCYP19A1NPC1L3MBTL1 | |
| SCHEMBL4959809 | 0.85 | HSD11B1 (0.36) | RIPK1 | |
| SCHEMBL4959812 | 0.85 | HSD11B1 (0.36) | RIPK1 | |
| SCHEMBL4968840 | 0.83 | HTR7 (0.46) | HTR2AHTR2CCYP19A1HTT | |
| SCHEMBL4968845 | 0.83 | HTR7 (0.46) | HTR2AHTR2CCYP19A1HTT | |
| SCHEMBL4962751 | 0.81 | CA2 (0.33) | CYP19A1NPC1L3MBTL1MAOBHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1871759-A1 | BENZODIOXANE AND BENZODIOXOLANE DERIVATIVES AND USES THEREOF | Wyeth a Corporation of the State of Delaware (US) | 2008-01-02 | — | — | EP | disclosed |
| WO-2006116158-A1 | BENZODIOXANE AND BENZODIOXOLANE DERIVATIVES AND USES THEREOF | WYETH (US) | 2006-11-02 | — | — | WO | disclosed |
| US-20060241172-A1 | Benzodioxane and benzodioxolane derivatives and uses thereof | WYETH (US) | 2006-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060241172-A1 | Benzodioxane and benzodioxolane derivatives and uses thereof | HTR2C, HTR1D, HTR1A | HTR2A 7/4885HTR2C 1/4885CYP19A1 326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.